Inhibition of stress-induced liganddependent EGFR activation

Details for Australian Patent Application No. 2004255439 (hide)

Owner Max-Planck-Gesellschaft zur Forderung der Wissenschaften e.V.

Inventors Ullrich, Axel; Fischer, Oliver

Agent Davies Collison Cave

Pub. Number AU-B-2004255439

PCT Pub. Number WO2005/004893

Priority 03015209.4 04.07.03 EP

Filing date 5 July 2004

Wipo publication date 20 January 2005

Acceptance publication date 6 January 2011

International Classifications

A61K 38/18 (2006.01) Medicinal preparations containing peptides - Growth factors

A61K 39/395 (2006.01) Medicinal preparations containing antigens or antibodies - Antibodies

A61K 45/06 (2006.01) Medicinal preparations containing active ingredients not provided for in groups

C12N 15/11 (2006.01) Mutation or genetic engineering - DNA or RNA fragments

Event Publications

2 February 2006 PCT application entered the National Phase

  PCT publication WO2005/004893 Priority application(s): WO2005/004893

6 January 2011 Application Accepted

  Published as AU-B-2004255439

12 May 2011 Standard Patent Sealed

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2004255441-Combinations of vasoactive agents and their use in the treatment of sexual dysfunctions

2004255436-Saquinavir mesylate oral dosage form